Evidence map›Paper›PMID 36593035›Full record

ArticleIn vivo (Athens, Greece)

Automated Non-coplanar Volumetric Modulated Arc Therapy Planning for Maxillary Sinus Carcinoma.

Shingo Ohira, Shoki Inui, Naoyuki Kanayama, Yoshihiro Ueda, Masayoshi Miyazaki, Masahiko Koizumi, Koji Konishi

Open access · diamondAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in In vivo (Athens, Greece). The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
2.5field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 8 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

Shingo OhiraDepartment of Radiation Oncology, Osaka International Cancer Institute, Osaka, Japan; shingo.oohira@oici.jp.
Shoki InuiDepartment of Radiation Oncology, Osaka International Cancer Institute, Osaka, Japan.
Naoyuki KanayamaDepartment of Radiation Oncology, Osaka International Cancer Institute, Osaka, Japan.
Yoshihiro UedaDepartment of Radiation Oncology, Osaka International Cancer Institute, Osaka, Japan.
Masayoshi MiyazakiDepartment of Radiation Oncology, Osaka International Cancer Institute, Osaka, Japan.
Masahiko KoizumiDepartment of Medical Physics and Engineering, Osaka University Graduate School of Medicine, Suita, Japan.
Koji KonishiDepartment of Radiation Oncology, Osaka International Cancer Institute, Osaka, Japan.
Osaka Medical Center for Cancer and Cardiovascular Diseases · JPOsaka University · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

BACKGROUND/

aimDosimetric parameters in volumetric modulated arc therapy (VMAT), non-coplanar VMAT (NC-VMAT), and automated NC-VMAT (HyperArc, HA) were compared for patients with maxillary sinus carcinoma (MSC). PATIENTS AND

methodsTwenty HA plans were generated to deliver 70.4, 64, and 46 Gy for planning target volumes with high (PTV1), intermediate (PTV2), and low risk (PTV3), respectively. The VMAT and NC-VMAT plans were retrospectively generated using the same optimized parameters as those used in the HA plans.

resultsFor PTV1, the three treatment plans provided comparable target coverages. For PTV2, the D

conclusionThe HA plans provided the best target coverage and OAR sparing compared with VMAT and NC-VMAT plans for patients with MSC.

Indexed as

CarcinomaRadiotherapy, Intensity-ModulatedHumansMaxillary SinusOrgans at RiskRadiotherapy DosageRadiotherapy Planning, Computer-AssistedRetrospective Studiesdose comparisonMaxillary sinus carcinomanon-coplanar volumetric modulated arc therapy

Identifiers

PMID36593035
PMCPMC9843778
OpenAlexW4313474523

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.